Key Details
Price
$0.94Annual Revenue
$9.99 MAnnual EPS
-$1.42Annual ROE
698.49%Beta
0.76Events Calendar
Next earnings date:
Mar 06, 2025Recent quarterly earnings:
Nov 07, 2024Recent annual earnings:
Mar 06, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
NEW YORK, NY / ACCESSWIRE / January 3, 2025 / If you suffered a loss on your Applied Therapeutics, Inc. (NASDAQ:APLT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/applied-therapeutics-inc-lawsuit-submission-form?prid=120572&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Applied Therapeutics, Inc. (NASDAQ:APLT) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Applied Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/applied-therapeutics-inc.
NEW YORK, NY / ACCESSWIRE / January 3, 2025 / If you suffered a loss on your Applied Therapeutics, Inc. (NASDAQ:APLT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/applied-therapeutics-inc-lawsuit-submission-form?prid=120415&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Applied Therapeutics, Inc. (NASDAQ: APLT) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Applied Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/applied-therapeutics-inc.
NEW YORK , Jan. 3, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Applied Therapeutics, Inc. ("Applied Therapeutics" or the "Company") (NASDAQ: APLT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Applied Therapeutics investors who were adversely affected by alleged securities fraud between January 3, 2024 and December 2, 2024.
NEW YORK, NY / ACCESSWIRE / January 3, 2025 / If you suffered a loss on your Applied Therapeutics, Inc. (NASDAQ:APLT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/applied-therapeutics-inc-lawsuit-submission-form?prid=120383&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / January 3, 2025 / If you suffered a loss on your Applied Therapeutics, Inc. (NASDAQ:APLT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/applied-therapeutics-inc-lawsuit-submission-form?prid=120529&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / January 2, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Applied Therapeutics, Inc. (NASDAQ: APLT) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Applied Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/applied-therapeutics-inc.
SAN DIEGO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of all investors who purchased or otherwise acquired Applied Therapeutics, Inc. (NASDAQ: APLT) securities between January 3, 2024 and December 2, 2024. Applied Therapeutics is a clinical-stage biopharmaceutical company committed to the development of novel drug candidates against validated molecular targets in rare diseases.
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”) (NASDAQ: APLT) securities between January 3, 2024 and December 2, 2024, inclusive (the “Class Period”). Applied Therapeutics investors have until February 18, 2025 to file a lead plaintiff motion. If.
FAQ
- What is the primary business of Applied Therapeutics?
- What is the ticker symbol for Applied Therapeutics?
- Does Applied Therapeutics pay dividends?
- What sector is Applied Therapeutics in?
- What industry is Applied Therapeutics in?
- What country is Applied Therapeutics based in?
- When did Applied Therapeutics go public?
- Is Applied Therapeutics in the S&P 500?
- Is Applied Therapeutics in the NASDAQ 100?
- Is Applied Therapeutics in the Dow Jones?
- When was Applied Therapeutics's last earnings report?
- When does Applied Therapeutics report earnings?
- Should I buy Applied Therapeutics stock now?